# Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease

Study · id `cardio:ct-nct02393612` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02393612](<https://clinicaltrials.gov/study/NCT02393612>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02393612

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

## Technical summary

Registry record NCT02393612. Randomized; triple masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 151 participants (enrolled count; ClinicalTrials.gov record NCT02393612, source copy `cardio:ctgov-nct02393612-2016-11-01`, retrieved 2026-10-31)
- Start date: 2012-10 (registry gives no type) (ClinicalTrials.gov record NCT02393612, source copy `cardio:ctgov-nct02393612-2016-11-01`, retrieved 2026-10-31)
- Primary completion: 2014-04 (actual) (ClinicalTrials.gov record NCT02393612, source copy `cardio:ctgov-nct02393612-2016-11-01`, retrieved 2026-10-31)
- Completion: 2014-04 (actual) (ClinicalTrials.gov record NCT02393612, source copy `cardio:ctgov-nct02393612-2016-11-01`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02393612-2016-11-01`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease
- Acronym: DAVICI
- Condition: Peripheral Arterial Disease
- Intervention (Drug): DP-R202
- Intervention (Drug): Anplag tab
- Lead sponsor: Alvogen Korea
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: 80724831bc0980b22d54db7396775cf921afd844b987a2f2fefa807435ee9cc7
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
